Revive Therapeutics Submits Cannabinoid Delivery Technology Findings Abstract for 29th International Conference on Polyphenols and the 9th Tannin Conference

Print
| Source: Revive Therapeutics Ltd.

TORONTO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel cannabinoid solutions, today announced that it has submitted an abstract for the XXIX International Conference on Polyphenols and the 9th Tannin Conference (“ICP + TC 2018”) that contains results from its research project with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.

“We are pleased to submit the results demonstrating a unique cannabinoid delivery technology for presentation at this year’s ICP + TC 2018 conference,” said Fabio Chianelli, President of Revive. “Revive is positioned to advance the development and commercialization of novel cannabinoid delivery technologies offering licensed medical cannabis producers and pharmaceutical companies new product opportunities in large global disease markets opportunities such as in pain, dermatology, and wound healing.”

The XXIX International Conference on Polyphenols (“ICP”) and the 9th Tannin Conference (“TC”) will be held July 16th through July 20th in Madison, Wisconsin.  Groupe Polyphénols, founded in 1972, is the world’s premier society of scientists in the fields of polyphenol chemistry, bioactivity, nutrition, industrial applications, synthesis, and ecology. Every two years, Groupe Polyphénols hosts the ICP.  The XXIX ICP will be the first one to be held in the United States.  In 2018, the ICP will also host the 9th Tannin Conference.  After the very successful joint meeting in 2014 in Nagoya, the Tannin Conference will continue this new tradition of meeting jointly with the ICP.  This conference coincides with the 30-year anniversary of the first North American Tannin Conference, held in Port Angeles Washington in August 1988.

About the Cannabinoid Delivery Technology

The delivery technology aims to deliver both synthetic cannabinoids and natural extracts of cannabis in a potential number of ways such as topical gels, creams or ointments, oral or transdermal patches, and oral dosages.  The delivery technology is a natural, non-toxic, biodegradable and biocompatible composite that combines a tannin material, which is derived from a plant group having antibacterial, antifungal, antioxidant and wound healing properties, and a chitosan material, which is derived from the crustacean group having blood-clotting and antimicrobial properties.  The delivery technology has rapid onset of action and controlled or sustained release potential capabilities and may allow to combine multiple cannabinoids or cannabis extracts in one formulation.  The Company seeks to develop novel products that target multi-billion dollar market opportunities such as pain (i.e. neuropathic, joint pain), dermatology (i.e. acne, psoriasis), wound healing applications (i.e. battle wounds, scarring), and liver diseases.

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. (TSX VENTURE:RVV)(OTCQB:RVVTF) is focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid-based pharmaceutical markets. Additional information on Revive is available at www.ReviveThera.com.

For more information please contact:
Craig Leon
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: (416) 272-5525
Email: craig@revivethera.com
Website: www.revivethera.com  

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward-looking information" that involves known and unknown risks and uncertainties, which are not comprised of historical facts, and most of which are beyond the control of Revive. Forward-looking statements include estimates and statements that describe Revive’s future plans, objectives or goals, including words to the effect that Revive or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the granting of a patent for Bucillamine for the treatment of gout; the potential efficacy and commercial viability of Bucillamine for treatment of gout and Bucillamine for the treatment of Cystinuria; expansion of the Bucillamine clinical testing program; the Company's drug research and development, and commercialization plans; the Company’s research, development and commercialization plans for plant-based therapies, including cannabinoids; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing results will justify commercialization of the Company's drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect and no assurance can be given that such events will occur in the disclosed time frames or at all.

Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Management's Discussion & Analysis for the period ended June 30, 2017 and Revive's other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.